

Figure 1

SEQUENCE LISTING

5 <110> WARNER-LAMBERT

 <120> Matrix metalloproteinase inhibitors

 <130> A0000434

10 <140>

 <141>

 <160> 1

15 <170> PatentIn Ver. 2.1

 <210> 1

 <211> 471

20 <212> PRT

 <213> Homo sapiens

 <400> 1

25 Met His Pro Gly Val Leu Ala Ala Phe Leu Phe Leu Ser Trp Thr His
 1 5 10 15

 Cys Arg Ala Leu Pro Leu Pro Ser Gly Gly Asp Glu Asp Asp Leu Ser
 20 25 30

30 Glu Glu Asp Leu Gln Phe Ala Glu Arg Tyr Leu Arg Ser Tyr Tyr His
 35 40 45

 Pro Thr Asn Leu Ala Gly Ile Leu Lys Glu Asn Ala Ala Ser Ser Met
 50 55 60

35 Thr Glu Arg Leu Arg Glu Met Gln Ser Phe Phe Gly Leu Glu Val Thr
 65 70 75 80

 Gly Lys Leu Asp Asp Asn Thr Leu Asp Val Met Lys Lys Pro Arg Cys
40 85 90 95

 Gly Val Pro Asp Val Gly Glu Tyr Asn Val Phe Pro Arg Thr Leu Lys
 100 105 110

45 Trp Ser Lys Met Asn Leu Thr Tyr Arg Ile Val Asn Tyr Thr Pro Asp
 115 120 125

 Met Thr His Ser Glu Val Glu Lys Ala Phe Lys Lys Ala Phe Lys Val
 130 135 140

50 Trp Ser Asp Val Thr Pro Leu Asn Phe Thr Arg Leu His Asp Gly Ile
 145 150 155 160

 Ala Asp Ile Met Ile Ser Phe Gly Ile Lys Glu His Gly Asp Phe Tyr
 165 170 175

 Pro Phe Asp Gly Pro Ser Gly Leu Leu Ala His Ala Phe Pro Pro Gly
 180 185 190

	Pro Asn Tyr Gly Gly Asp Ala His Phe Asp Asp Asp Glu Thr Trp Thr			
	195	200	205	
5	Ser Ser Ser Lys Gly Tyr Asn Leu Phe Leu Val Ala Ala His Glu Phe			
	210	215	220	
10	Gly His Ser Leu Gly Leu Asp His Ser Lys Asp Pro Gly Ala Leu Met			
	225	230	235	240
	Phe Pro Ile Tyr Thr Tyr Thr Gly Lys Ser His Phe Met Leu Pro Asp			
	245	250	255	
15	Asp Asp Val Gln Gly Ile Gln Ser Leu Tyr Gly Pro Gly Asp Glu Asp			
	260	265	270	
	Pro Asn Pro Lys His Pro Lys Thr Pro Asp Lys Cys Asp Pro Ser Leu			
	275	280	285	
20	Ser Leu Asp Ala Ile Thr Ser Leu Arg Gly Glu Thr Met Ile Phe Lys			
	290	295	300	
	Asp Arg Phe Phe Trp Arg Leu His Pro Gln Gln Val Asp Ala Glu Leu			
25	305	310	315	320
	Phe Leu Thr Lys Ser Phe Trp Pro Glu Leu Pro Asn Arg Ile Asp Ala			
	325	330	335	
30	Ala Tyr Glu His Pro Ser His Asp Leu Ile Phe Ile Phe Arg Gly Arg			
	340	345	350	
	Lys Phe Trp Ala Leu Asn Gly Tyr Asp Ile Leu Glu Gly Tyr Pro Lys			
	355	360	365	
35	Lys Ile Ser Glu Leu Gly Leu Pro Lys Glu Val Lys Lys Ile Ser Ala			
	370	375	380	
	Ala Val His Phe Glu Asp Thr Gly Lys Thr Leu Leu Phe Ser Gly Asn			
40	385	390	395	400
	Gln Val Trp Arg Tyr Asp Asp Thr Asn His Ile Met Asp Lys Asp Tyr			
	405	410	415	
45	Pro Arg Leu Ile Glu Glu Asp Phe Pro Gly Ile Gly Asp Lys Val Asp			
	420	425	430	
	Ala Val Tyr Glu Lys Asn Gly Tyr Ile Tyr Phe Phe Asn Gly Pro Ile			
	435	440	445	
50	Gln Phe Glu Tyr Ser Ile Trp Ser Asn Arg Ile Val Arg Val Met Pro			
	450	455	460	
	Ala Asn Ser Ile Leu Trp Cys			
55	465	470		

Figure 2




Figure 3: Synthesis example 1 binding mode




Figure 4: Synthesis example 1 binding mode




Figure 5: Synthesis example 10 binding mode




Figure 6: fused Bicyclic Pyrimidones-binding mode




Figure 7: Synthesis example 39 binding mode




Figure 8: Synthesis example 57 binding mode




Figure 9: Coordinates in the space of the hydrophobic groups and hydrogen bond acceptors of the pharmacophore

